IBSA is focusing on the development of Hi-Tech medical devices with registered CE mark, which means a fast introduction in all countries recognising the EU certification.

Please find here below the available licensing opportunities.

Description
Highly purified hyaluronic acid of bio-fermentative origin, MW of about one million KDa, pre-filled syringes of 2 ml, 0.8% (16 mg).

Indication
Pain and decreased mobility as part of degenerative or traumatic conditions of the joints (viscosupplementation).

Status
Approved CE mark, already marketed in several EU and non-EU countries.

Claims
High quality and safety (biotechnological), best effective MW, lower concentration for an easy injection, competitive cost.

Countries available for licensing
Available on exclusive or semi-exclusive basis for Germany, UK, Scandinavian countries, Eastern Europe, India, Indonesia, China, Latin America and USA.

For details see Page Extensions

For information please contact:

Description
Plain hyaluronic acid (Ialuset^®) or hyaluronic acid plus silver sulphadiazine (Ialuset Plus^®).

Indication
Wound healing, burns: with (Ialuset Plus^®) or without (Ialuset^®) infective complications.

Status
Approved CE mark, already marketed in several EU and non-EU countries.

Countries available for licensing
Available on semi-exclusive basis for several EU and non-EU countries recognising the European CE mark.

For details see Page Extensions

For information please contact: